AMY1A: A Potential Drug Target and Biomarker for Alpha-amylase 1C

Target Name: AMY1A

NCBI ID: G276

AMY1A

AMY1A: A Potential Drug Target and Biomarker for Alpha-amylase 1C

Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by the accumulation of neurofibrillary tangles and the loss of nerve cells. One of the hallmark hallmarks of Alzheimer's disease is the presence of beta-amylase (尾-amylase) positive neurons in the brain, which are thought to play a crucial role in the production of amyloid plaques, a hallmark of the disease. However, the exact molecular mechanisms underlying the pathogenesis of Alzheimer's disease remain unclear.

Recent studies have identified several potential drug targets and biomarkers for Alzheimer's disease. One of these targets is alpha-amylase 1C (AMY1C), a gene that encodes a protein involved in the breakdown of amyloid peptides. The presence of AMY1C positive neurons in the brain is highly correlated with the severity of Alzheimer's disease.

In this article, we will discuss the AMY1A protein, its function, and its potential as a drug target and biomarker for Alzheimer's disease.

Function and Interaction of AMY1C

AMY1C is a member of the superfamily of structurally similar enzymes known as serine proteases. These enzymes belong to the trypsin-like family 2 (TL2) and are involved in the cleavage of a wide variety of substrates, including proteins, nucleic acids, and lipids.

AMY1C is a 16-kDa protein that is expressed in various tissues and organs, including the brain, pancreas, and liver. It is predominantly localized to the endoplasmic reticulum (ER) and is thought to play a role in the ER-associated degradation (ERAD) of proteins.

One of the well-established functions of AMY1C is its role in the degradation of beta-amylase (尾-amylase), a protein that is involved in the production of amyloid plaques. 尾-amylase is cleaved by AMY1C into its constituent amino acids, which are then catenated into amyloid peptides. The presence of 尾-amylase positive neurons in the brain is highly correlated with the severity of Alzheimer's disease.

In addition to its role in the degradation of 尾-amylase, AMY1C has been shown to play other roles in the pathogenesis of Alzheimer's disease. For example, it has been shown to be involved in the regulation of cellular signaling pathways that are involved in the development of neurofibrillary tangles and the loss of nerve cells.

Potential as a Drug Target

The potential use of AMY1C as a drug target is based on its role in the production of amyloid peptides and its involvement in the pathogenesis of Alzheimer's disease. Several studies have shown that blocking the activity of AMY1C can significantly reduce the formation of amyloid peptides and improve survival in animal models of Alzheimer's disease.

One of the main targets for AMY1C is its role in the production of beta-amylase, which is a key component of the amyloid peptides that are thought to contribute to the formation of neurofibrillary tangles and the loss of nerve cells in Alzheimer's disease. Several small molecules have been shown to be effective in blocking the activity of AMY1C and reducing the production of amyloid peptides.

Another potential target for AMY1C is its role in the regulation of cellular signaling pathways that are involved in

Protein Name: Amylase Alpha 1A

Functions: Calcium-binding enzyme that initiates starch digestion in the oral cavity (PubMed:12527308). Catalyzes the hydrolysis of internal (1->4)-alpha-D-glucosidic bonds, yielding a mixture of maltose, isomaltose, small amounts of glucose as well as small linear and branched oligosaccharides called dextrins (PubMed:12527308)

The "AMY1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AMY1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets